CytoDyn ’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ( " CytoDyn " or the " Company " ), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials